KR-62436 is a competitive inhibitor of dipeptidyl peptidase-IV (DPP-IV). DPP-IV is a serine protease which inactivates glucagon-like peptide (GLP-1); IC50 0.1-0.8 μM; GLP-1 is a potent stimulus for insulin secretion and inducer of satiety after food intake, but it has a very short action (1 min) because it is rapidly degraded by DPP-IV; blocking DPP-IV increases GLP-1 action and increases plasma insulin levels; DPP-IV inhibitors and KR-62436 have clinical potential as anti-diabetic agents
European journal of pharmacology, 518(1), 63-70 (2005-08-18)
Dipeptidyl peptidase-IV (DPP-IV) is involved in the inactivation of glucagon-like peptide-1 (GLP-1), a potent insulinotropic peptide. Thus, DPP-IV inhibition can be an effective approach to treat type 2 diabetes mellitus by potentiating insulin secretion. This study describes the biological effects
Molecular cancer research : MCR, 19(1), 61-73 (2020-10-01)
The biological influence of antidiabetic drugs on cancer cells and diabetic cancer patients has not yet been completely elucidated. We reported that a dipeptidyl peptidase (DPP)-4 inhibitor accelerates mammary cancer metastasis by inducing epithelial-mesenchymal transition (EMT) through the CXCL12/CXCR4/mTOR axis.
Dipeptidyl peptidase (DPP)-4 is a multifunctional glycoprotein involved in various biological and pathologic processes. DPP-4 has been widely recognized as a therapeutic target for type 2 diabetes mellitus but is also implicated in the development of human malignancies. Here, we
We offers many products related to neuropeptidases for your research needs.
Questions
Évaluations
★★★★★ Aucune valeur de notation
Filtres actifs
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..